High impact imaging AmberGen offers hyper-multiomic mass spectrometric spatial imaging with MaxOmic service and reagents, enabling comprehensive spatial omics data from a single run. Potential sales opportunity: position as a turnkey solution for biotechs and CROs seeking rapid, multiparametric tissue analysis to de-risk drug development and accelerate biomarker discovery.

Integrated services The MaxOmic service lab provides turnkey testing alongside reagent sales for researchers to perform imaging in-house. Potential sales opportunity: upsell bundled offerings combining service analytics with consumables and training to capture full-lifecycle customer spend and build recurring revenue.

Strategic partnerships AmberGen has established collaborations with Bruker on MALDI-HIplex-IHC and MALDI-IHC reagents, and includes senior leadership with industry-experienced hires. Potential sales opportunity: leverage partner ecosystem and credibility to co-sell with instrument vendors and CROs, expanding reach into platforms already in customers’ labs.

Regulatory and grants Past NIH SBIR funding and advanced imaging capabilities signal proof of concept and funding readiness. Potential sales opportunity: target grant-funded programs and biotech startups pursuing translational research, offering consulting and cost-effective imaging workflows aligned with grant milestones.

Expansion-ready market Product breadth spans drug distribution mapping, spatial omics layers, multiplex proteomics, transcriptomics, and glycomics, with AI-powered correlative analysis. Potential sales opportunity: address pharmaceutical and CRO pipelines needing multiplexed spatial data to inform candidate selection, IND-enabling studies, and biomarker stratification across small molecule, ASO, and ADC modalities.